Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04713202
Recruitment Status : Recruiting
First Posted : January 19, 2021
Last Update Posted : April 14, 2021
Sponsor:
Collaborator:
TerSera Therapeutics LLC
Information provided by (Responsible Party):
Pashtoon Kasi, MD, MS, Big Ten Cancer Research Consortium

Brief Summary:
The NET-PACS trial is a Prospective Assessment of patients with neuroendocrine tumors and current or prior history of Carcinoid Syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl. The main goal of the study is to demonstrate the feasibility of serial in-depth assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing treatment with PRRT using telotristat ethyl compared to placebo. We aim to report and describe from a patient's perspective the multi-faceted impact of carcinoid syndrome in patients with NETs and the changes on treatment while getting PRRT using telotristat ethyl compared to placebo.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumors Carcinoid Syndrome Diarrhea Drug: Telotristat ethyl Drug: Peptide Receptor Radionuclide Therapy Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400
Actual Study Start Date : March 3, 2021
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2024


Arm Intervention/treatment
Experimental: Telotristat Ethyl + PRRT

Telotristat ethyl, 250 mg, PO, three times daily, continuous.

+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks

Drug: Telotristat ethyl
Telotristat Ethyl, 250mg

Drug: Peptide Receptor Radionuclide Therapy
Peptide Receptor Radionuclide Therapy
Other Name: PRRT

Placebo Comparator: Placebo + PRRT

Placebo, PO, three times daily, continuous.

+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks

Drug: Peptide Receptor Radionuclide Therapy
Peptide Receptor Radionuclide Therapy
Other Name: PRRT

Other: Placebo
Placebo




Primary Outcome Measures :
  1. FACT-QS global QoL Score [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]

    Feasibility of in-depth assessment of changes and improvement on treatment in patients undergoing treatment as determined by FACT-CS global QoL with PRRT using telotristat ethyl compared to placebo. The FACT-CS global QoL is the primary endpoint. Scores will be derived using FACIT guidelines and will range from 0 to 12 with higher scores denoting a better level of functioning.

    A repeated measures ANOVA will be applied and statistical significance of fixed effects of treatment arm, time and treatment arm by time interaction will be assessed using a Wilks' Lambda Approximate F test.



Secondary Outcome Measures :
  1. To describe and report from a patient's perspective the multi-faceted impact of carcinoid syndrome in patients with NETs and the changes on treatment while getting PRRT using telotristat ethyl compared to placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in QoL as measured by the identified FACT-CS scales. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.

  2. ATo report changes in patient reported outcomes (PRO) in the diarrhea domain in patients undergoing PRRT receiving telotristat ethyl versus placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in QoL Diarrhea domain as measured by the identified FACT-CS scales. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.

  3. To report changes in patient reported outcomes (PRO) in the flushing domain in patients undergoing PRRT receiving telotristat ethyl versus placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in QoL as measured by the identified FACT-CS scales in the flushing domain. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.

  4. To estimate the need of rescue short-acting somatostatin receptor antagonist in patients undergoing PRRT receiving telotristat ethyl versus placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in frequency of rescue short acting somatostatin receptor antagonist use. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.

  5. To estimate the weight-gain in patients undergoing PRRT receiving telotristat ethyl versus placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in weight. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.

  6. To estimate the changes in bowel movement frequency and/or consistency in patients undergoing PRRT receiving telotristat ethyl versus placebo. [ Time Frame: From enrollment until completion of study therapy or subject withdrawal, up to six months ]
    Linear mixed effects regression model will be utilized to describe longitudinal changes in frequency and/or changes in consistency of bowel movements. Fixed effects for treatment arm, time and treatment arm by time interaction along with a random effect to account for the longitudinally correlated nature of repeated questionnaire measurements will be included. Graphical plots of the estimated mean and associated 95% confidence intervals by time point in the study will be produced.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Males and females, aged 18 and older
  • Histologically-confirmed neuroendocrine tumor (GI or other primary)
  • Presence of somatostatin receptors as by either Ga-68 dotatate imaging or Octreoscan or comparable method, which is a requirement for PRRT (Lutathera ®). Disease does not need to be measurable per RECIST since it is not uncommon to have non-target lesions but not meet criteria for RECIST as long as presence of somatostatin receptors can be demonstrated. NOTE: Patients undergoing other types of PRRT would not be eligible for this clinical trial.
  • Eligible for treatment with PRRT (Lutathera®) according to institutional practice and product label.
  • Patient with current or prior history of symptomatic carcinoid syndrome or carcinoid diarrhea as per investigator assessment. Note: prior history and current controlled carcinoid patients are eligible.
  • Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 28 days prior to registration.
  • Life expectancy greater than 12 weeks as per investigator opinion
  • ECOG performance status 0-2
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum βhCG) within 7 days prior to study registration. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. See exclusion 4 for WOCBP definition.

Exclusion Criteria:

  • Surgery, radiotherapy, within 4 weeks; chemotherapy, or other investigational therapy within 2 weeks prior to study registration, or 5 half-lives of a drug, whichever is shorter.
  • Uncontrolled congestive heart failure prior to study registration. Patients can be considered eligible if the disease is controlled at the date of randomization.
  • Subject with another significant medical, psychiatric, or surgical conditions, currently uncontrolled by treatment, which may interfere with completion of the study as per investigator opinion.
  • Women of childbearing potential (WOCBP), must agree to use appropriate method(s) of contraception. Women are considered to be of childbearing potential unless are surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).
  • WOCBP must agree to use appropriate method(s) of contraception from the time of informed consent until 7 months post-treatment completion. Complete abstinence is also an acceptable form of contraception.
  • Men who are sexually active with WOCBP must agree to use appropriate method(s) of contraception from the first dose of study drug until 4 months post-treatment completion. Complete abstinence is also an acceptable form of contraception.
  • Telotristat ethyl tablets contain lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take telotristat ethyl.
  • Concomitant medications: Any other herbal or alternative medicines being used as an anti-cancer treatment are not allowed. NOTE: if patient is receiving a drug that is a CYP3A4 substrate, strongly consider switching to an alternate drug if possible. The latter is more of a recommendation, not an exclusion criterion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04713202


Contacts
Layout table for location contacts
Contact: Dylan Cregar 317-634-5842 ext 38 dcregar@hoosiercancer.org
Contact: Leaetta Hyer, RN 317-634-5842 ext 26 lhyer@hoosiercancer.org

Locations
Layout table for location information
United States, Iowa
University of Iowa Hospital and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Sara Nordman    319-353-4585    sara-nordman@uiowa.edu   
Principal Investigator: Pashtoon Kasi, MS         
Sponsors and Collaborators
Pashtoon Kasi, MD, MS
TerSera Therapeutics LLC
Investigators
Layout table for investigator information
Principal Investigator: Pashtoon Kasi, MD University of Iowa Holden Comprehensive
Study Chair: Al B Benson, MD Northwestern University
Study Chair: David Cella, PhD Northwestern University
Layout table for additonal information
Responsible Party: Pashtoon Kasi, MD, MS, Clinical Assistant Professor of Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation, Big Ten Cancer Research Consortium
ClinicalTrials.gov Identifier: NCT04713202    
Other Study ID Numbers: BTCRC-GI19-400
First Posted: January 19, 2021    Key Record Dates
Last Update Posted: April 14, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Carcinoid Tumor
Malignant Carcinoid Syndrome
Syndrome
Diarrhea
Serotonin Syndrome
Disease
Pathologic Processes
Signs and Symptoms, Digestive
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders